Skip to main content

Table 1 Patient demographics and baseline clinical characteristics

From: Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database

Characteristic ITT
n = 784
PP
n = 359
Age (years, mean ± SD) 37.1 ± 12.5; 39.3 ± 13
   (range) 18 to 26 not reported
Sex, n (%)   
   Male 547 (69.8%) 246 (68.5%)
   Female 237 (30.2%) 113 (31.5%)
Diagnosis   
   Schizophrenia 580 (74.0%) 266 (74.1%)
   Schizoaffective disorder 175 (22.3%) 84 (23.4%)
   Other 29 (3.7%) 9 (2.5%)
Time since diagnosis (years, mean ± SD) 10.6 ± 9.5 12.2 ± 10.4
Unemployed, n (%) 705 (89.9%) 319 (88.9%)
CGI-S score (mean ± SD) 4.52 ± 1.04 4.48 ± 1.04
Mean GAF score (mean ± SD) 42.9 ± 14.5 42.3 ± 14.5
Community treatment order 394 (50.3%) 188 (52.3%)
Full hospitalisations in previous 12-months 604 (77.0%) 267 (74.4%)
  1. CGI-S clinical global impression--severity; GAF global assessment of functioning